Cargando…

Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells

The major drawback of current anti-angiogenic therapies is drug resistance, mainly caused by overexpression of the transcription factor, hypoxia-inducible factor 1α (HIF-1α) as a result of treatment-induced hypoxia, which stimulates cancer cells to develop aggressive and immunosuppressive phenotypes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rauca, Valentin-Florian, Licarete, Emilia, Luput, Lavinia, Sesarman, Alina, Patras, Laura, Bulzu, Paul, Rakosy-Tican, Elena, Banciu, Manuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107259/ https://www.ncbi.nlm.nih.gov/pubmed/30138430 http://dx.doi.org/10.1371/journal.pone.0202827

Ejemplares similares

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis
por: Negrea, Giorgiana, et al.
Publicado: (2022)

In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin
por: Luput, Lavinia, et al.
Publicado: (2018)

Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5‐fluorouracil in vivo
por: Luput, Lavinia, et al.
Publicado: (2020)

Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment
por: Licarete, Emilia, et al.
Publicado: (2020)

Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo
por: Patras, Laura, et al.
Publicado: (2021)

A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy
por: Barbălată, Cristina Ioana, et al.
Publicado: (2021)

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach
por: Tefas, Lucia Ruxandra, et al.
Publicado: (2017)

Biologically Active Ajuga Species Extracts Modulate Supportive Processes for Cancer Cell Development
por: Rauca, Valentin-Florian, et al.
Publicado: (2019)

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
por: Laws, A. L., et al.
Publicado: (1995)

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
por: Ching, L. M., et al.
Publicado: (1992)

Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
por: Ching, L-M, et al.
Publicado: (2002)

Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro
por: Patras, Laura, et al.
Publicado: (2020)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
por: Ching, L. M., et al.
Publicado: (1995)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

The effect of UV light on division capacity of Helianthus mollis L. protoplasts
por: vesa, Simona, et al.
Publicado: (2005)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
por: Moilanen, E., et al.
Publicado: (1998)

Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
por: Cao, Z, et al.
Publicado: (1999)

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
por: Philpott, M., et al.
Publicado: (1997)

Phytochemical Profile and Selective Cytotoxic Activity of a Solanum bulbocastanum Dun. Methanolic Extract on Breast Cancer Cells
por: Paraschiv, Mihnea, et al.
Publicado: (2022)

Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
por: Steinmetz, Martin, et al.
Publicado: (2010)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma
por: Mangelinck, Adèle, et al.
Publicado: (2021)

Simvastatin-romidepsin combination kills bladder cancer cells synergistically
por: Okubo, Kazuki, et al.
Publicado: (2021)

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
por: Ching, L. M., et al.
Publicado: (1998)

Passive transfer of collagen XVII-specific antibodies induces sustained blistering disease in adult mice
por: Chiriac, Mircea Teodor, et al.
Publicado: (2013)

Simvastatin and Losartan Differentially and Synergistically Inhibit Atherosclerosis in Apolipoprotein E(-/-) Mice
por: Lee, Bok-Soo, et al.
Publicado: (2012)

Introgression of Two Broad-Spectrum Late Blight Resistance Genes, Rpi-Blb1 and Rpi-Blb3, From Solanum bulbocastanum Dun Plus Race-Specific R Genes Into Potato Pre-breeding Lines
por: Rakosy-Tican, Elena, et al.
Publicado: (2020)

The Use of the QbD Approach to Optimize the Co-Loading of Simvastatin and Doxorubicin in Liposomes for a Synergistic Anticancer Effect
por: Barbalata, Cristina-Ioana, et al.
Publicado: (2022)

Exploring the Synergistic Effect of Simvastatin in Oral Health Applications: A Literature Review
por: Kabra, Sakshi, et al.
Publicado: (2023)

Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach
por: Pan, Shu-Ting, et al.
Publicado: (2015)

New Phenotypes of Potato Co-induced by Mismatch Repair Deficiency and Somatic Hybridization
por: Rakosy-Tican, Elena, et al.
Publicado: (2019)

Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects
por: Kater, Ana-Lucia A, et al.
Publicado: (2010)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Visualization of Lokiarchaeia and Heimdallarchaeia (Asgardarchaeota) by Fluorescence In Situ Hybridization and Catalyzed Reporter Deposition (CARD-FISH)
por: Salcher, Michaela M., et al.
Publicado: (2020)

Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss
por: Dai, Bingyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3g2gn2tl0m1engd465l9kuqb0